AGA临床实践更新:外分泌胰腺功能不全的流行病学、评估与管理专家综述
美国胃肠病学会(AGA)发布专家综述,以最佳实践建议形式阐述外分泌胰腺功能不全(EPI)的流行病学、评估与管理。建议包括高危与中危人群识别、粪便弹性蛋白酶作为首选初始检查、胰腺酶替代治疗(PERT)的用法与监测,以及营养状态评估。
要点
- 慢性胰腺炎、复发性急性胰腺炎、胰腺导管腺癌、囊性纤维化及胰腺手术史者应怀疑EPI。
- 粪便弹性蛋白酶是首选初始检查,<100 μg/g提示EPI,100-200 μg/g为不确定。
- 确诊EPI需PERT,成人每餐至少40,000 USP单位脂肪酶,零食减半,随餐服用。
核心结论
- EPI常被漏诊,患者常未获适当治疗,亟需提高对该病的认识和治疗水平。
研究设计与样本
- 美国胃肠病学会(AGA)临床实践更新委员会(CPUC)与AGA理事会委托并批准的专家综述,经内部同行评议和《Gastroenterology》标准外部同行评议,基于已发表文献综述与专家意见形成最佳实践建议。
- 因未进行系统评价,这些最佳实践建议不附带关于证据质量或推荐强度的正式评级。
主要发现
- EPI应在高危临床情况(如慢性胰腺炎、复发性急性胰腺炎、胰腺导管腺癌、囊性纤维化及既往胰腺手术)患者中怀疑。
- EPI应在中危临床情况(如乳糜泻和克罗恩病等十二指肠疾病、既往肠道手术、长期糖尿病及高分泌状态如卓-艾综合征)患者中考虑。
- EPI临床特征包括脂肪泻伴或不伴腹泻、体重减轻、腹胀、排气过多、脂溶性维生素缺乏及蛋白质-热量营养不良。
- 粪便弹性蛋白酶水平<100 μg/g粪便为EPI的良好证据,100-200 μg/g为不确定;粪便脂肪检测很少需要,且须在高脂饮食下进行。
- 横断面影像学方法(计算机断层扫描、磁共振成像和内镜超声)不能识别EPI,但在良恶性胰腺疾病诊断中起重要作用。
关键数值与推荐
- 最佳实践建议1:EPI应在高危临床情况患者中怀疑。
- 最佳实践建议2:EPI应在中危临床情况患者中考虑。
- 最佳实践建议4:粪便弹性蛋白酶试验是最合适的初始检查,必须在半固体或固体粪便标本上进行;<100 μg/g粪便为EPI的良好证据,100-200 μg/g为不确定。
- 最佳实践建议12:PERT应随餐服用,成人每餐初始治疗至少40,000 USP单位脂肪酶,零食时用其一半;后续剂量可根据餐量和脂肪含量调整。
- 最佳实践建议15:应监测EPI并获取营养状态基线测量(体重指数、生活质量测量和脂溶性维生素水平);应获取基线双能X线吸收测定扫描并每1-2年重复。
临床怎么用
- EPI一旦确诊,需要胰腺酶替代治疗(PERT);若不治疗,将导致脂肪吸收不良和营养不良相关并发症,对生活质量产生负面影响。
- PERT制剂均来源于猪源,在等效剂量下效果相同;非肠溶制剂需要H2受体拮抗剂或质子泵抑制剂治疗。
- 常规补充和监测脂溶性维生素水平是适当的;饮食调整包括低-中等脂肪饮食、少量多餐,避免极低脂肪饮食。
- PERT治疗成功的指标包括脂肪泻及相关胃肠道症状减少、体重、肌肉量和肌肉功能增加以及脂溶性维生素水平改善。
局限性
- 因未进行系统评价,这些最佳实践建议不附带关于证据质量或推荐强度的正式评级。
- 呼气试验和直接胰腺功能测试有前景,但在美国未广泛可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: Exocrine pancreatic insufficiency (EPI) is a disorder caused by the failure of the pancreas to deliver a minimum/threshold level of specific pancreatic digestive enzymes to the intestine, leading to the maldigestion of nutrients and macronutrients, resulting in their variable deficiencies. EPI is frequently underdiagnosed and, as a result, patients are often not treated appropriately. There is an urgent need to increase awareness of and treatment for this condition. The aim of this American Gastroenterological Association (AGA) Clinical Practice Update Expert Review was to provide Best Practice Advice on the epidemiology, evaluation, and management of EPI. METHODS: This Expert Review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: EPI should be suspected in patients with high-risk clinical conditions, such as chronic pancreatitis, relapsing acute pancreatitis, pancreatic ductal adenocarcinoma, cystic fibrosis, and previous pancreatic surgery. BEST PRACTICE ADVICE 2: EPI should be considered in patients with moderate-risk clinical conditions, such as duodenal diseases, including celiac and Crohn's disease; previous intestinal surgery; longstanding diabetes mellitus; and hypersecretory states (eg, Zollinger-Ellison syndrome). BEST PRACTICE ADVICE 3: Clinical features of EPI include steatorrhea with or without diarrhea, weight loss, bloating, excessive flatulence, fat-soluble vitamin deficiencies, and protein-calorie malnutrition. BEST PRACTICE ADVICE 4: Fecal elastase test is the most appropriate initial test and must be performed on a semi-solid or solid stool specimen. A fecal elastase level <100 μg/g of stool provides good evidence of EPI, and levels of 100-200 μg/g are indeterminate for EPI. BEST PRACTICE ADVICE 5: Fecal elastase testing can be performed while on pancreatic enzyme replacement therapy. BEST PRACTICE ADVICE 6: Fecal fat testing is rarely needed and must be performed when on a high-fat diet. Quantitative testing is generally not practical for routine clinical use. BEST PRACTICE ADVICE 7: Response to a therapeutic trial of pancreatic enzymes is unreliable for EPI diagnosis. BEST PRACTICE ADVICE 8: Cross-sectional imaging methods (computed tomography scan, magnetic resonance imaging, and endoscopic ultrasound) cannot identify EPI, although they play an important role in the diagnosis of benign and malignant pancreatic disease. BEST PRACTICE ADVICE 9: Breath tests and direct pancreatic function tests hold promise, but are not widely available in the United States. BEST PRACTICE ADVICE 10: Once EPI is diagnosed, treatment with pancreatic enzyme replacement therapy (PERT) is required. If EPI is left untreated, it will result in complications related to fat malabsorption and malnutrition, having a negative impact on quality of life. BEST PRACTICE ADVICE 11: PERT formulations are all derived from porcine sources and are equally effective at equivalent doses. There is a need for H2 or proton pump inhibitor therapy with non-enteric-coated preparations. BEST PRACTICE ADVICE 12: PERT should be taken during the meal, with the initial treatment of at least 40,000 USP units of lipase during each meal in adults and one-half of that with snacks. The subsequent dosage can be adjusted based on the meal size and fat content. BEST PRACTICE ADVICE 13: Routine supplementation and monitoring of fat-soluble vitamin levels are appropriate. Dietary modifications include a low-moderate fat diet with frequent smaller meals and avoiding very-low-fat diets. BEST PRACTICE ADVICE 14: Measures of successful treatment with PERT include reduction in steatorrhea and associated gastrointestinal symptoms; a gain of weight, muscle mass, and muscle function; and improvement in fat-soluble vitamin levels. BEST PRACTICE ADVICE 15: EPI should be monitored and baseline measurements of nutritional status should be obtained (body mass index, quality-of-life measure, and fat-soluble vitamin levels). A baseline dual-energy x-ray absorptiometry scan should be obtained and repeated every 1-2 years.
引用
- Whitcomb DC, Buchner AM, Forsmark CE, et al. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology. 2023. PMID: 37737818. doi:10.1053/j.gastro.2023.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。